Zobrazeno 1 - 3
of 3
pro vyhledávání: '"A. I. Khryapa"'
Autor:
E. V. Borodavina, A. Yu. Shurinov, S. I. Kutukova, E. N. Nedozorova, A. V. Malanchuk, Yu. V. Semenchenko, S. M. Povarkov, K. V. Narovenkova, A. V. Khodkevich, Yu. V. Komoza, K. A. Kofanova, S. P. Dmitriev, E. B. Vasilyeva, S. A. Shikhamirova, M. N. Gorshenina, L. N. Volodina, O. A. Snezhko, O. A. Stativko, D. V. Xenodokhov, Yu. G. Dzhemageldieva, A. I. Khryapa, D. M. Ulimaeva, E. M. Dagba, M. V. Volkonsky, V. M. Filippova, M. O. Skorina, O. V. Romanchuk, I. I. Andrienko, M. V. Shorin, A. A. Ishchenko, R. A. Dumbrava, M. B. Bolieva, F. V. Tsarakhova, Z. A. Gojieva, S. S. Dzhamirzaeva, P. Z. Aidaeva, M. O. Maximov, I. S. Usoltseva, A. O. Milyukova, O. V. Toporkova, V. D. Sychev, S. A. Rudakov, S. T. Sagdieva, M. A. Klochikhin, V. V. Molokova, R. A. Skotnikov, E. N. Yeremina, Yu. A. Panaseikin, Ya. A. Tyugina, Yu. I. Murzina, S. O. Podvyaznikov
Publikováno v:
Опухоли головы и шеи, Vol 13, Iss 4, Pp 73-82 (2024)
Introduction. The multikinase inhibitors have demonstrated high clinical efficacy in treatment of the radioiodine refractory differentiated thyroid cancer. At the same time, the inclusion criteria in the studies has reflected a minimum set of charact
Externí odkaz:
https://doaj.org/article/d9a4c33879434bc1a8e12f558ea03e1d
Autor:
E. V. Borodavina, P. A. Isaev, A. Yu. Shurinov, P. O. Rumyantsev, V. V. Krylov, K. M. Petrosyan, A. D. Kaprin, S. A. Ivanov, S. O. Podvyaznikov, I. S. Romanov, A. M. Mudunov, K. Yu. Slashchuk, R. S. Zhikhorev, M. V. Volkonsky, R. M. Chagova, I. R. Suslova, A. I. Khryapa, A. Kh. Lepshokova, N. L. Fadeeva, A. R. Safarova, L. P. Kaleykina, E. V. Lymar, E. M. Chernyakova, O. A. Snezhko, A. E. Zinkovskaya, F. F. Mufazalov, E. S. Kuzmina, Yu. V. Druzhinina, Sh. I. Musin, M. R. Mukhitova, A. I. Khasanova, S. Z. Safina, S. L. Kirienko
Publikováno v:
Опухоли головы и шеи, Vol 10, Iss 1, Pp 65-72 (2020)
Background. The implementation of tyrosine kinase inhibitors into clinical practice improved treatment outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Lenvatinib is recommended as a first-line drug for these p
Externí odkaz:
https://doaj.org/article/90b3f88358a64191b3df59c14333279c
Autor:
A. I. Khryapa, E. M. Chernyakova, F. F. Mufazalov, E. V. Lymar, S. A. Ivanov, K. Yu. Slashchuk, N. L. Fadeeva, R. M. Chagova, V. V. Krylov, A. R. Safarova, A. M. Mudunov, S. Z. Safina, M. R. Mukhitova, A. I. Khasanova, S. O. Podvyaznikov, K. M. Petrosyan, I. R. Suslova, R. S. Zhikhorev, A. Kh. Lepshokova, P. A. Isaev, S. L. Kirienko, Yu. V. Druzhinina, I. S. Romanov, E. S. Kuzmina, Andrey Kaprin, Sh. I. Musin, O. A. Snezhko, A. Yu. Shurinov, L. P. Kaleykina, A. E. Zinkovskaya, Pavel O. Rumyantsev, M. V. Volkonsky, E. V. Borodavina
Publikováno v:
Opuholi Golovy i Šei, Vol 10, Iss 1, Pp 65-72 (2020)
Background. The implementation of tyrosine kinase inhibitors into clinical practice improved treatment outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Lenvatinib is recommended as a first-line drug for these p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a048aaf0f080825f30978d7d8770c6d6
https://ogsh.abvpress.ru/jour/article/view/478
https://ogsh.abvpress.ru/jour/article/view/478